Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Uroxin 4G + fosfomycin
- Development stage
- Unknown
- Lead developer
- Pharmasuisse Laboratories
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Small Molecules, Peptides
- Administration
- Oral
01
Overview
Uroxin 4G + fosfomycin is a combination therapy consisting of the multi-ingredient dietary supplement Uroxin 4G and the broad-spectrum antibiotic fosfomycin trometamol. Uroxin 4G is a nutraceutical formulation containing D-mannose, collagen, hyaluronic acid, chondroitin sulphate, propolis, quercetin (as Proqutin®), and the probiotic *Bacillus coagulans*. Fosfomycin acts by inhibiting bacterial cell wall synthesis through the inactivation of the enzyme UDP-N-acetylglucosamine enolpyruvyl transferase (MurA). The combination is designed to provide a synergistic effect by combining direct antimicrobial activity with the anti-adhesive properties of D-mannose, the mucosal-protective effects of glycosaminoglycans and collagen, and the anti-inflammatory and microbiome-modulating benefits of quercetin, propolis, and probiotics. This regimen is being evaluated by the University of Campania Luigi Vanvitelli in Phase 4 clinical trials (specifically the IMProBaCist-Q study) for the prevention of recurrent urinary tract infections (UTIs) and the improvement of quality of life in women.
- Brand names
- Monuril
- Other names
- Combination of dietary supplement and fosfomycinUroxin 4G plus fosfomycin trometamolUroxin4G plus fosfomycin trometamolUroxin-4G plus fosfomycin trometamolUroxin 4G plus fosfomycinUroxin4G plus fosfomycinUroxin-4G plus fosfomycin
02
Targets
MurA (UDP-N-acetylglucosamine 1-carboxyvinyltransferase)FimH (Type 1 fimbrial adhesin)
Beyond the preview
Go deeper on Uroxin 4G + fosfomycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Uroxin 4G + fosfomycin.